http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Apr 2026 08:30:28 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+raises+%245+million+in+registered+direct+offering/26347877.html <p>Outlook Therapeutics Inc. (NASDAQ: OTLK) announced it entered into a definitive agreement for a $5.0 million registered direct offering priced at-the-market under Nasdaq rules.</p> <p>The biopharmaceutical company will sell 16,129,033 shares of common stock or pre-funded warrants at $0.31 per share. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 16,129,033 additional shares at an exercise price of $0.31 per share.</p> <p>The unregistered warrants will become exercisable after stockholder approval of the underlying share issuance and an amendment to increase authorized shares. The warrants will expire five years following their exercisability date and registration statement effectiveness.</p> <p>H.C. http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+raises+%245+million+in+registered+direct+offering/26347877.html Wed, 22 Apr 2026 08:30:28 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+raises+%245+million+in+registered+direct+offering/26347877.html <p>Outlook Therapeutics Inc. (NASDAQ: OTLK) announced it entered into a definitive agreement for a $5.0 million registered direct offering priced at-the-market under Nasdaq rules.</p> <p>The biopharmaceutical company will sell 16,129,033 shares of common stock or pre-funded warrants at $0.31 per share. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 16,129,033 additional shares at an exercise price of $0.31 per share.</p> <p>The unregistered warrants will become exercisable after stockholder approval of the underlying share issuance and an amendment to increase authorized shares. The warrants will expire five years following their exercisability date and registration statement effectiveness.</p> <p>H.C. http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+raises+%245+million+in+registered+direct+offering/26347877.html Wed, 22 Apr 2026 08:30:28 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+raises+%245+million+in+registered+direct+offering/26347877.html <p>Outlook Therapeutics Inc. (NASDAQ: OTLK) announced it entered into a definitive agreement for a $5.0 million registered direct offering priced at-the-market under Nasdaq rules.</p> <p>The biopharmaceutical company will sell 16,129,033 shares of common stock or pre-funded warrants at $0.31 per share. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 16,129,033 additional shares at an exercise price of $0.31 per share.</p> <p>The unregistered warrants will become exercisable after stockholder approval of the underlying share issuance and an amendment to increase authorized shares. The warrants will expire five years following their exercisability date and registration statement effectiveness.</p> <p>H.C. http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+raises+%245+million+in+registered+direct+offering/26347877.html Wed, 22 Apr 2026 08:30:28 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+raises+%245+million+in+registered+direct+offering/26347877.html <p>Outlook Therapeutics Inc. (NASDAQ: OTLK) announced it entered into a definitive agreement for a $5.0 million registered direct offering priced at-the-market under Nasdaq rules.</p> <p>The biopharmaceutical company will sell 16,129,033 shares of common stock or pre-funded warrants at $0.31 per share. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 16,129,033 additional shares at an exercise price of $0.31 per share.</p> <p>The unregistered warrants will become exercisable after stockholder approval of the underlying share issuance and an amendment to increase authorized shares. The warrants will expire five years following their exercisability date and registration statement effectiveness.</p> <p>H.C. http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+raises+%245+million+in+registered+direct+offering/26347877.html Wed, 22 Apr 2026 08:30:28 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+raises+%245+million+in+registered+direct+offering/26347877.html <p>Outlook Therapeutics Inc. (NASDAQ: OTLK) announced it entered into a definitive agreement for a $5.0 million registered direct offering priced at-the-market under Nasdaq rules.</p> <p>The biopharmaceutical company will sell 16,129,033 shares of common stock or pre-funded warrants at $0.31 per share. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 16,129,033 additional shares at an exercise price of $0.31 per share.</p> <p>The unregistered warrants will become exercisable after stockholder approval of the underlying share issuance and an amendment to increase authorized shares. The warrants will expire five years following their exercisability date and registration statement effectiveness.</p> <p>H.C. http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+raises+%245+million+in+registered+direct+offering/26347877.html Wed, 22 Apr 2026 08:30:28 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html <p align="justify">ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bQzyIbuY1S1c8NNDMh4A2hzE87gcFpSJZ7r8zCcRTMd_D70oO2OVWYfq-cQ1QPidf64g6OJlsXr8xP3fruIvRv-6UCaW_IZlxHqsjY_0rWxrJ2y40_0oowvlZvqouJFG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html Wed, 22 Apr 2026 08:30:00 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html <p align="justify">ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bQzyIbuY1S1c8NNDMh4A2hzE87gcFpSJZ7r8zCcRTMd_D70oO2OVWYfq-cQ1QPidf64g6OJlsXr8xP3fruIvRv-6UCaW_IZlxHqsjY_0rWxrJ2y40_0oowvlZvqouJFG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html Wed, 22 Apr 2026 08:30:00 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html <p align="justify">ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bQzyIbuY1S1c8NNDMh4A2hzE87gcFpSJZ7r8zCcRTMd_D70oO2OVWYfq-cQ1QPidf64g6OJlsXr8xP3fruIvRv-6UCaW_IZlxHqsjY_0rWxrJ2y40_0oowvlZvqouJFG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html Wed, 22 Apr 2026 08:30:00 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html <p align="justify">ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bQzyIbuY1S1c8NNDMh4A2hzE87gcFpSJZ7r8zCcRTMd_D70oO2OVWYfq-cQ1QPidf64g6OJlsXr8xP3fruIvRv-6UCaW_IZlxHqsjY_0rWxrJ2y40_0oowvlZvqouJFG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html Wed, 22 Apr 2026 08:30:00 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html <p align="justify">ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bQzyIbuY1S1c8NNDMh4A2hzE87gcFpSJZ7r8zCcRTMd_D70oO2OVWYfq-cQ1QPidf64g6OJlsXr8xP3fruIvRv-6UCaW_IZlxHqsjY_0rWxrJ2y40_0oowvlZvqouJFG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html Wed, 22 Apr 2026 08:30:00 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html <p align="justify">ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bQzyIbuY1S1c8NNDMh4A2hzE87gcFpSJZ7r8zCcRTMd_D70oO2OVWYfq-cQ1QPidf64g6OJlsXr8xP3fruIvRv-6UCaW_IZlxHqsjY_0rWxrJ2y40_0oowvlZvqouJFG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html Wed, 22 Apr 2026 08:30:00 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html <p align="justify">ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bQzyIbuY1S1c8NNDMh4A2hzE87gcFpSJZ7r8zCcRTMd_D70oO2OVWYfq-cQ1QPidf64g6OJlsXr8xP3fruIvRv-6UCaW_IZlxHqsjY_0rWxrJ2y40_0oowvlZvqouJFG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html Wed, 22 Apr 2026 08:30:00 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html <p align="justify">ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bQzyIbuY1S1c8NNDMh4A2hzE87gcFpSJZ7r8zCcRTMd_D70oO2OVWYfq-cQ1QPidf64g6OJlsXr8xP3fruIvRv-6UCaW_IZlxHqsjY_0rWxrJ2y40_0oowvlZvqouJFG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html Wed, 22 Apr 2026 08:30:00 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html <p align="justify">ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bQzyIbuY1S1c8NNDMh4A2hzE87gcFpSJZ7r8zCcRTMd_D70oO2OVWYfq-cQ1QPidf64g6OJlsXr8xP3fruIvRv-6UCaW_IZlxHqsjY_0rWxrJ2y40_0oowvlZvqouJFG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html Wed, 22 Apr 2026 08:30:00 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html <p align="justify">ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bQzyIbuY1S1c8NNDMh4A2hzE87gcFpSJZ7r8zCcRTMd_D70oO2OVWYfq-cQ1QPidf64g6OJlsXr8xP3fruIvRv-6UCaW_IZlxHqsjY_0rWxrJ2y40_0oowvlZvqouJFG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,129,033 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.31 per share of common stock (or per pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+%245.0+Million+Registered+Direct+Offering+Priced+At-the-Market+Under+Nasdaq+Rules/26347851.html Wed, 22 Apr 2026 08:30:00 -0400 A.60012004 O.01304637 O.14475130 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html <p align="justify">ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUIjEkLNjLejEPXr9Yj1j9_cbz2xTdJd61JMLnFEC1HjAEtrtyRU6gW0a2I-0IQj-L-UbELvjPURzkmrqUh7wDhAlQZhkYMjp9vuRtJAkmlDzOuETWk3NBMqFkrc8BYh" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html Tue, 07 Apr 2026 08:50:00 -0400 A.06822034 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html <p align="justify">ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUIjEkLNjLejEPXr9Yj1j9_cbz2xTdJd61JMLnFEC1HjAEtrtyRU6gW0a2I-0IQj-L-UbELvjPURzkmrqUh7wDhAlQZhkYMjp9vuRtJAkmlDzOuETWk3NBMqFkrc8BYh" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html Tue, 07 Apr 2026 08:50:00 -0400 A.06822034 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html <p align="justify">ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUIjEkLNjLejEPXr9Yj1j9_cbz2xTdJd61JMLnFEC1HjAEtrtyRU6gW0a2I-0IQj-L-UbELvjPURzkmrqUh7wDhAlQZhkYMjp9vuRtJAkmlDzOuETWk3NBMqFkrc8BYh" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html Tue, 07 Apr 2026 08:50:00 -0400 A.06822034 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html <p align="justify">ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUIjEkLNjLejEPXr9Yj1j9_cbz2xTdJd61JMLnFEC1HjAEtrtyRU6gW0a2I-0IQj-L-UbELvjPURzkmrqUh7wDhAlQZhkYMjp9vuRtJAkmlDzOuETWk3NBMqFkrc8BYh" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html Tue, 07 Apr 2026 08:50:00 -0400 A.06822034 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html <p align="justify">ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUIjEkLNjLejEPXr9Yj1j9_cbz2xTdJd61JMLnFEC1HjAEtrtyRU6gW0a2I-0IQj-L-UbELvjPURzkmrqUh7wDhAlQZhkYMjp9vuRtJAkmlDzOuETWk3NBMqFkrc8BYh" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html Tue, 07 Apr 2026 08:50:00 -0400 A.06822034 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html <p align="justify">ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUIjEkLNjLejEPXr9Yj1j9_cbz2xTdJd61JMLnFEC1HjAEtrtyRU6gW0a2I-0IQj-L-UbELvjPURzkmrqUh7wDhAlQZhkYMjp9vuRtJAkmlDzOuETWk3NBMqFkrc8BYh" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html Tue, 07 Apr 2026 08:50:00 -0400 A.06822034 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html <p align="justify">ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUIjEkLNjLejEPXr9Yj1j9_cbz2xTdJd61JMLnFEC1HjAEtrtyRU6gW0a2I-0IQj-L-UbELvjPURzkmrqUh7wDhAlQZhkYMjp9vuRtJAkmlDzOuETWk3NBMqFkrc8BYh" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html Tue, 07 Apr 2026 08:50:00 -0400 A.06822034 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html <p align="justify">ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUIjEkLNjLejEPXr9Yj1j9_cbz2xTdJd61JMLnFEC1HjAEtrtyRU6gW0a2I-0IQj-L-UbELvjPURzkmrqUh7wDhAlQZhkYMjp9vuRtJAkmlDzOuETWk3NBMqFkrc8BYh" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html Tue, 07 Apr 2026 08:50:00 -0400 A.06822034 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html <p align="justify">ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUIjEkLNjLejEPXr9Yj1j9_cbz2xTdJd61JMLnFEC1HjAEtrtyRU6gW0a2I-0IQj-L-UbELvjPURzkmrqUh7wDhAlQZhkYMjp9vuRtJAkmlDzOuETWk3NBMqFkrc8BYh" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html Tue, 07 Apr 2026 08:50:00 -0400 A.06822034 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html <p align="justify">ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUIjEkLNjLejEPXr9Yj1j9_cbz2xTdJd61JMLnFEC1HjAEtrtyRU6gW0a2I-0IQj-L-UbELvjPURzkmrqUh7wDhAlQZhkYMjp9vuRtJAkmlDzOuETWk3NBMqFkrc8BYh" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics+Announces+Formal+Dispute+Resolution+Request+for+ONS-5010LYTENAVA%E2%84%A2+%28bevacizumab-vikg%29+Accepted+by+FDA/26280965.html Tue, 07 Apr 2026 08:50:00 -0400 A.06822034 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW